[
  {
    "ts": null,
    "headline": "BD Merges Biosciences & Diagnostics Business With Waters",
    "summary": "BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.",
    "url": "https://finnhub.io/api/news?id=8aa67feffa66822cd5f20e85d99a08216364ba8db914f75972e7acad8a414154",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834840,
      "headline": "BD Merges Biosciences & Diagnostics Business With Waters",
      "id": 139049621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WAT",
      "source": "Yahoo",
      "summary": "BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.",
      "url": "https://finnhub.io/api/news?id=8aa67feffa66822cd5f20e85d99a08216364ba8db914f75972e7acad8a414154"
    }
  },
  {
    "ts": null,
    "headline": "Unusual volume S&P500 stocks in Wednesday's session",
    "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
    "url": "https://finnhub.io/api/news?id=033c5014df7c27f24f0c5a6c10ab1fc5c81841acbdd49f4222e3e47a86487724",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770833104,
      "headline": "Unusual volume S&P500 stocks in Wednesday's session",
      "id": 139047010,
      "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
      "related": "WAT",
      "source": "ChartMill",
      "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
      "url": "https://finnhub.io/api/news?id=033c5014df7c27f24f0c5a6c10ab1fc5c81841acbdd49f4222e3e47a86487724"
    }
  },
  {
    "ts": null,
    "headline": "Waters resumed with an In Line at Evercore ISI",
    "summary": "Evercore ISI resumed coverage of Waters (WAT) with an In Line rating and $360 price target. Shares have dipped by 13% post the Becton Dickinson (BDX) Life Sci transaction due to mixed results and cautious guidance, says the analyst, who notes that debate centers around management’s confidence in deal merits versus short-term concerns.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news",
    "url": "https://finnhub.io/api/news?id=52b04a18c8424e54ecf78686d0252a3eacff84b3290e33cfea881e4a39a45657",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815483,
      "headline": "Waters resumed with an In Line at Evercore ISI",
      "id": 139042531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WAT",
      "source": "Yahoo",
      "summary": "Evercore ISI resumed coverage of Waters (WAT) with an In Line rating and $360 price target. Shares have dipped by 13% post the Becton Dickinson (BDX) Life Sci transaction due to mixed results and cautious guidance, says the analyst, who notes that debate centers around management’s confidence in deal merits versus short-term concerns.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news",
      "url": "https://finnhub.io/api/news?id=52b04a18c8424e54ecf78686d0252a3eacff84b3290e33cfea881e4a39a45657"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Equal-Weight on Waters, Lowers Price Target to $355",
    "summary": "Wells Fargo  analyst Brandon Couillard   maintains Waters (NYSE:WAT) with a Equal-Weight and lowers the price target from $415 to $355.",
    "url": "https://finnhub.io/api/news?id=d12952f6eaa0dd477fa3b159856ac8d4ca8f4f90ffd9d0c3d29f1b05d6219dd5",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770807630,
      "headline": "Wells Fargo Maintains Equal-Weight on Waters, Lowers Price Target to $355",
      "id": 139056731,
      "image": "",
      "related": "WAT",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Brandon Couillard   maintains Waters (NYSE:WAT) with a Equal-Weight and lowers the price target from $415 to $355.",
      "url": "https://finnhub.io/api/news?id=d12952f6eaa0dd477fa3b159856ac8d4ca8f4f90ffd9d0c3d29f1b05d6219dd5"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Reinstates Overweight on Waters, Announces $400 Price Target",
    "summary": "Barclays  analyst Luke Sergott   reinstates Waters (NYSE:WAT) with a Overweight and announces $400 price target.",
    "url": "https://finnhub.io/api/news?id=744ecbd1c0db9647e4a25330273a7be4bd98efde6e06b905989a77c4ad5f8548",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770803094,
      "headline": "Barclays Reinstates Overweight on Waters, Announces $400 Price Target",
      "id": 139043058,
      "image": "",
      "related": "WAT",
      "source": "Benzinga",
      "summary": "Barclays  analyst Luke Sergott   reinstates Waters (NYSE:WAT) with a Overweight and announces $400 price target.",
      "url": "https://finnhub.io/api/news?id=744ecbd1c0db9647e4a25330273a7be4bd98efde6e06b905989a77c4ad5f8548"
    }
  }
]